Last reviewed · How we verify

SOMATROGON

FDA-approved approved Recombinant protein Quality 35/100

SOMATROGON is a drug. It is currently FDA-approved (first approved 2022) for Growth failure due to inadequate growth hormone secretion.

Somatrogon is a marketed drug indicated for growth failure due to inadequate growth hormone secretion, positioning it in a niche but critical therapeutic area. Its key strength lies in its mechanism of action, which addresses the underlying deficiency directly, potentially offering a more targeted treatment option compared to broader alternatives. The primary risk to consider is the key composition patent expiry in 2028, which could lead to increased competition from generics and biosimilars.

At a glance

Generic nameSOMATROGON
ModalityRecombinant protein
PhaseFDA-approved
First approval2022

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SOMATROGON

What is SOMATROGON?

SOMATROGON is a Recombinant protein drug, indicated for Growth failure due to inadequate growth hormone secretion.

What is SOMATROGON used for?

SOMATROGON is indicated for Growth failure due to inadequate growth hormone secretion.

When was SOMATROGON approved?

SOMATROGON was first approved on 2022.

What development phase is SOMATROGON in?

SOMATROGON is FDA-approved (marketed).

What are the side effects of SOMATROGON?

Common side effects of SOMATROGON include Injection site reactions, Nasopharyngitis, Headache, Pyrexia, Anemia, Cough.

Related